Rocket Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:9IP1 Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
19 May 26	Sell€998	John Militello	Individual	384	€2.60
19 May 26	Sell€1,721	Martin Wilson	Individual	662	€2.60
19 May 26	Sell€6,262	Gaurav Shah	Individual	2,409	€2.60
13 May 26	Sell€2,633	John Militello	Individual	855	€3.08
13 May 26	Sell€8,401	Gaurav Shah	Individual	2,728	€3.08
13 May 26	Sell€10,350	Martin Wilson	Individual	3,361	€3.08
07 May 26	Sell€57,552	Sarbani Chaudhuri	Individual	17,650	€3.26
18 Feb 26	Sell€16,921	Gaurav Shah	Individual	5,990	€2.82
18 Feb 26	Sell€3,887	Martin Wilson	Individual	1,376	€2.82
18 Feb 26	Sell€3,268	John Militello	Individual	1,157	€2.82
13 Feb 26	Sell€10,398	John Militello	Individual	3,726	€2.79
13 Feb 26	Sell€34,267	Gaurav Shah	Individual	12,279	€2.79
13 Feb 26	Sell€34,194	Martin Wilson	Individual	12,253	€2.79
02 Jan 26	Buy€29,288	Elisabeth Bjork	Individual	10,000	€2.93
18 Nov 25	Sell€16,171	Gaurav Shah	Individual	6,276	€2.58
18 Nov 25	Sell€2,798	John Militello	Individual	1,086	€2.58
18 Nov 25	Sell€6,558	Jonathan Schwartz	Individual	2,545	€2.58
18 Nov 25	Sell€4,241	Martin Wilson	Individual	1,646	€2.58
27 Aug 25	Buy€29,377	Elisabeth Bjork	Individual	10,000	€2.94
19 Aug 25	Sell€4,146	Martin Wilson	Individual	1,592	€2.63
19 Aug 25	Sell€2,762	John Militello	Individual	1,060	€2.63
19 Aug 25	Sell€6,478	Jonathan Schwartz	Individual	2,485	€2.63
14 Aug 25	Sell€31,377	Martin Wilson	Individual	12,109	€2.59
14 Aug 25	Sell€18,250	John Militello	Individual	7,043	€2.59
14 Aug 25	Sell€28,920	Jonathan Schwartz	Individual	11,161	€2.59
03 Jul 25	Sell€3,619	Aaron Ondrey	Individual	1,477	€2.45

Insider Trading Volume

Insider Buying: 9IP1 insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of 9IP1?
Owner Type	Number of Shares	Ownership Percentage
Private Companies	104,927	0.0961%
Individual Insiders	3,764,884	3.45%
General Public	6,671,737	6.11%
Hedge Funds	17,687,772	16.2%
Institutions	80,964,229	74.1%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 73.1% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
16.2%	RTW Investments, LP	17,687,772	€42.0m	0%	0.45%
7.17%	BlackRock, Inc.	7,831,365	€18.6m	-0.9%	no data
4.68%	Citigroup Inc.	5,107,708	€12.1m	-2.64%	0.01%
4.3%	Vanguard Portfolio Management, LLC	4,690,215	€11.1m	0%	no data
4.11%	State Street Global Advisors, Inc.	4,485,989	€10.7m	164%	no data
3.46%	Vanguard Capital Management, LLC	3,775,736	€9.0m	0%	no data
3.27%	Maverick Capital, Ltd.	3,567,372	€8.5m	42%	0.1%
2.9%	Newtyn Management, LLC	3,165,900	€7.5m	19.5%	0.77%
2.86%	Millennium Management LLC	3,118,124	€7.4m	74.7%	no data
2.84%	Teachers Insurance and Annuity Association-College Retirement Equities Fund	3,101,182	€7.4m	1,890%	no data
2.78%	Marshall Wace LLP	3,038,715	€7.2m	11,400%	0.01%
2.72%	AQR Capital Management, LLC	2,969,901	€7.1m	345%	no data
2%	Geode Capital Management, LLC	2,189,256	€5.2m	3.25%	no data
1.99%	D. E. Shaw & Co., L.P.	2,169,625	€5.2m	-17.8%	no data
1.89%	Monaco Asset Management S.A.M.	2,058,303	€4.9m	-31.1%	1.48%
1.34%	Gaurav Shah	1,467,962	€3.5m	48.5%	no data
1.22%	Eaton Vance Management	1,329,315	€3.2m	32.6%	no data
1.19%	UBS Asset Management AG	1,298,434	€3.1m	757%	no data
1.01%	Two Sigma Investments, LP	1,097,623	€2.6m	-48.5%	no data
0.99%	The Goldman Sachs Group, Inc.	1,078,087	€2.6m	51.8%	no data
0.94%	Federated Hermes, Inc.	1,023,747	€2.4m	16.2%	no data
0.93%	Point72 Asset Management, L.P.	1,012,126	€2.4m	99.3%	no data
0.87%	Opaleye Management Inc.	955,000	€2.3m	0%	0.28%
0.79%	T. Rowe Price Group, Inc.	859,874	€2.0m	-9%	no data
0.68%	JP Morgan Asset Management	738,007	€1.8m	72.2%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/14 00:37
End of Day Share Price	2026/06/12 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Rocket Pharmaceuticals, Inc. is covered by 23 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jason Zemansky	BofA Global Research
Whitney Ijem	Canaccord Genuity
Joshua Schimmer	Cantor Fitzgerald & Co.